Laxmi Organic in FY26: A margin-reset year, with Dahej commissioning and R&D scale-up setting up the next phase

Laxmi Organic Industries Limited went into FY26 in a difficult operating backdrop for chemicals, and the consolidated numbers reflect a year of pressure on profitability. For FY26, the company reported revenue of INR 28,467 million, EBITDA of INR 1,714 million, and PAT of INR 794 million. EBITDA margin compressed to 6.0 percent from 9.4 percent in FY25, while PAT margin fell to 2.8 percent from 3.8 percent.

Q4FY26 offered a modest sequential improvement. Revenue for the quarter was INR 7,353 million versus INR 6,780 million in Q3FY26, and adjusted EBITDA margin improved sharply quarter-on-quarter, which the company attributes mainly to better price realizations.

Segment mix: Essentials stays resilient, Specialities remains the profit anchor

The company operates two business units: Essentials and Specialties. In FY26, Essentials remained the larger revenue contributor. Segment revenue disclosed in the presentation shows Essentials revenue at INR 20,268 million and Specialities revenue at INR 7,791 million (noting the company’s disclosure that FY26 revenue excludes a one-time litigation settlement gain). On this basis, Essentials accounted for about 71 percent of FY26 segment revenue, with Specialities at about 29 percent.

Within profitability, the presentation indicates that Specialities continues to contribute the majority of adjusted EBITDA. For FY26, adjusted EBITDA contribution is shown as 75 percent from Specialities and 25 percent from Essentials. That gap between revenue share and EBITDA share underscores the company’s positioning: Essentials is designed as a scale-led, high-volume, operationally efficient platform, while Specialities is intended to monetize technology platforms and customer development work.

However, FY26 also highlighted where the pressure was most visible. Specialities revenue declined 18 percent year on year (to INR 7,791 million from INR 9,496 million in FY25), even as Essentials revenue was flat year on year at INR 20,268 million.

Notes: The presentation states FY26 includes a one-time gain of INR 407 million from a litigation settlement and one-time expenses including Labour Code impact of INR 38 million and a supply chain redesign project cost. It also notes revenue from operations for Q3 and FY26 excludes the one-time gain.

De-risking indicators: exports and customer concentration

Two risk-reduction metrics in the deck are notable because they are expressed as time-series data.

First, exports remain structurally relevant. The presentation discloses exports as 32 percent of revenue in FY26, with domestic at 68 percent. Over the last four fiscal years presented, exports have ranged from 30 percent to 36 percent, indicating that the company has maintained international participation rather than becoming purely domestic.

Second, customer concentration has reduced. Revenue from the top 10 customers is disclosed at 20 percent in FY26, down from 23 percent in FY25, 27 percent in FY24, and 34 percent in FY23. This trend suggests progress in diversifying the customer base, which is particularly important for a company serving end-markets such as pharma, agro-chemicals, pigments, and printing and packaging.

The presentation also provides export region mix and industry-wise revenue mix. For FY26 export revenue, Europe is the largest region at 35 percent, followed by Africa at 22 percent, Rest of Asia Pacific at 17 percent, Middle East at 14 percent, Americas at 7 percent and China at 6 percent.

Investment cycle: Dahej commissioning and the scale-up engine

The clearest execution narrative in the presentation is the Dahej capex update. The company lays out a dated timeline of regulatory and project milestones, culminating in the statement that the Dahej site received CTO in Q1 FY27 for first phase production and that commercial delivery started thereafter, along with chemical charging.

Dahej is positioned as a brownfield site with meaningful headroom. The deck discloses 116 acres of land with less than 20 percent land occupancy. It also indicates a proposed product mix of 60 percent specialties and 40 percent essentials at Dahej.

Parallel to physical expansion, the company is scaling development infrastructure. The Mahape, Navi Mumbai innovation centre, inaugurated in February 2025, is described as a roughly 30,000 square foot facility with an investment of USD 8 million. The presentation details lab, kilo lab, and pilot capabilities including high-pressure and specialized metallurgy reactors, supporting process development and scale-up.

This strategy aligns with how the company frames its next growth phase. The deck explicitly describes a shift toward a customer-centric business approach, stating that this shift helped the company gain market and increase wallet share in the past two years despite a subdued chemical environment.

Cash flow and balance sheet: capex visible, leverage higher

FY26 cash generation from operations improved versus FY25. Net cash from operating activities was INR 1,749 million in FY26 compared with INR 1,080 million in FY25. Investing cash flows were negative at INR 4,036 million, reflecting the capex cycle, and financing cash flows were positive at INR 2,472 million.

On the balance sheet, capital work-in-progress increased to INR 6,517 million at March 2026 from INR 3,984 million at March 2025, consistent with ongoing projects. Borrowings shifted materially: non-current borrowings increased to INR 4,932 million at March 2026 from INR 425 million at March 2025, while current borrowings reduced to INR 477 million from INR 2,107 million.

What FY26 set up for FY27

FY26 reads like a transition year in which operating profitability was pressured, while the company pushed ahead on its next set of growth enablers. The near-term financial outcome was weaker year on year, but the disclosures also show tangible progress on two building blocks: Dahej moving into the commissioning and delivery stage for phase one, and a materially upgraded R and D and pilot infrastructure at Mahape.

The company’s stated strategic intent in Specialities is also explicit: fluor assets started delivering revenue in FY26, and the company aims to have minimum 20 percent sales from new products. If Dahej ramps as planned and new products scale through the development pipeline, the key question for investors will be whether margin recovery can follow the asset build-out in a normalized chemical environment.